Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Clozapine (HB1607)
Description:Prototypic, atypical antipsychotic, binds to both serotonin and dopamine receptors
Purity:>99%
- Description:
Water soluble prototypic, atypical antipsychotic. Binds to both serotonin and dopamine receptors.
Purity:>98%
Dihydroergocristine mesylate (HB1611)
Description:5-HT antagonist. Also partial agonist at adrenergic and dopaminergic receptors.
Purity:>98%
Haloperidol hydrochloride (HB1842)
Description:Dopamine receptor antagonist with partial D2-like selectivity
Purity:>99%
Homovanillic acid (HB1902)
Description:Fluorimetric reagent. Catecholamine metabolite.
Purity:>99%
- Description:
Inhibits α-MSH release inhibitors. Also increase dopamine levels.